Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia.

ABSTRACT:

Background

In people with chronic-phase chronic myeloid leukemia (CML) receiving imatinib and achieving major molecular response (MMR), dose reduction may decrease adverse events but may be associated with a loss of molecular response. Whether digital droplet polymerase chain reaction (ddPCR) can identify persons in whom dose reduction might be unsuccessful is unknown.

Methods

Data from 716 consecutive subjects who achieved MMR after initial imatinib therapy (400 mg/day) were obtained. A total of 486 subjects remained on full-dose imatinib, whereas 230 subjects had their dose reduced to 300 or 200 mg/day. The outcomes of these cohorts were compared via landmark and propensity score matching analyses.

Results

Imatinib dose reduction showed no significant effect on the

SUBMITTER: Li Z 

PROVIDER: S-EPMC11694160 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature